UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
/X/ Annual Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
(Fee Required)
For the fiscal year ended December 31, 1996
/ / Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
(No Fee Required)
For the transition period from
__________________________to__________________________
Commission file Number 0-26832
Lumisys Incorporated
(Exact name of registrant as specified in its charter)
Delaware 77-0133232
(State or other jurisdiction of (I.R.S. Employer Identification
incorporation or organization) Number)
225 Humboldt Court
Sunnyvale, CA 94089
(408)-733-6565
(address, including zip code and telephone number, including area code, of
registrant's principal executive offices)
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Title of each Class
Common, $0.001 par value
Indicate by check mark whether the registrant (1) has filed all reports
required to filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. /X/ Yes / / No
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. / /
As of February 3, 1997, there were issued and outstanding 6,425,578 shares
of Common Stock; the aggregate market value of the shares of such stock
held by nonaffiliates of the registrant was $53,540,775 as of the same
date, assuming solely for purposes of this calculation that all directors
and executive officers of the Registrant are "affiliates". This
determination of affiliate status is not necessarily a conclusive
determination for other purposes.
Documents Incorporated By Reference
Portions of Lumisys Incorporated Proxy Statement for its Annual
Stockholders Meeting to by held on May 12, 1997 (Part III)
PART I.
Risk Factors
Except for the historical information contained herein, the discussion in
this Form 10-K for the year ended December 31, 1996 contains forward-
looking statements that involve risks and uncertainties. The Company's
actual results could differ materially from those discussed here. Factors
that could cause or contribute to such differences include, but are not
limited to, those discussed in this section, as well as in the sections
entitled "Business" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations," and those discussed in other
documents filed by the Company with the Securities and Exchange
Commission.
SIGNIFICANT FLUCTUATIONS IN OPERATING RESULTS. There can be no assurance
that the Company will be profitable on a quarterly or annual basis in the
future. The Company has experienced quarterly fluctuations in operating
results caused by various factors, including the timing of orders by major
customers, customer inventory levels, shifts in product mix, the
incurrence of acquisition-related costs and general conditions in the
healthcare industry which have reduced capital equipment budgets and
delayed or reduced the adoption of teleradiology, and expects that these
fluctuations will continue.
The Company typically does not obtain long-term volume purchase contracts
from its customers, and a substantial portion of the Company's backlog is
scheduled for delivery within 90 days or less. Customers may cancel
orders and change volume levels or delivery times without penalty.
Quarterly sales and operating results therefore depend on the volume and
timing of the backlog as well as bookings received during the quarter. A
significant portion of the Company's operating expenses are fixed, and
planned expenditures are based primarily on sales forecasts and product
development programs. If sales do not meet the Company's expectations in
any given period, the materially adverse impact on operating results may
be magnified by the Company's inability to adjust operating expenses
sufficiently or quickly enough to compensate for such a shortfall.
Furthermore, the Company's gross margins may decrease in the future due to
increasing sales of lower margin products and volume discounts. Results
of operations in any period should not be considered indicative of the
results to be expected for any future period. Fluctuations in operating
results may also result in fluctuations in the price of the Company's
Common Stock. See "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and "Business - Manufacturing."
DEPENDENCE ON EMERGING TELERADIOLOGY MARKET; UNDERTAINTY OF MARKET
ACCEPTANCE. The Company's success is dependent on market acceptance of
its new and existing products. Substantially all of the Company's
revenues are derived from the sales of medical image digitizers for the
teleradiology and other medical markets. Although development of the
teleradiology market has been predicted for the last ten to fifteen years,
the market for the Company's products is still relatively undeveloped and
may not experience material expansion in the near future, if at all.
Furthermore, there can be no assurance that sales of new products will
achieve significant market acceptance in the future. In addition, third
party payers, such as governmental programs and private insurance plans,
can indirectly affect the pricing or the relative attractiveness of the
Company's products by regulating the maximum amount of reimbursement that
they will provide for the taking, storing and interpretation of medical
images. A decrease in the reimbursement amounts for radiological
procedures may decrease the amount which physicians, clinics and hospitals
are able to charge patients for such services. As a result, adoption of
teleradiology may slow as capital investment budgets are reduced, thereby
significantly reducing the demand for the Company's products. See
"Business - Products and Applications" and "-Third Party Reimbursement."
SIGNIFICANT RISKS ASSOCIATED WITH FUTURE ACQUISITIONS. The Company
expects to pursue acquisitions of complementary technologies, product
lines or businesses in the future. The integration of any future
acquisitions will require special attention from management, which may
temporarily distract its attention from the day-to-day business of the
Company. Any future acquisitions will also require integration of the
companies' product offerings and coordination of research and development
and sales and marketing activities. Furthermore, as a result of
acquisitions, the Company may enter markets in which it has no or little
direct prior experience. There can also be no assurance that the Company
will be able to retain key technical personnel of an acquired company or
recruit new management personnel for the acquired businesses, or that the
Company will, or may in the future, realize any benefits as a result of
such acquisitions. Future acquisitions by the Company may result in
potentially dilutive issuances of equity securities, the incurrence of
debt, one-time acquisition charges and amortization expenses related to
goodwill and intangible assets, each of which could be significant and
could materially adversely affect the Company's financial condition and
results of operations. In addition, the Company believes that it may be
required to expand and enhance its financial and management controls,
reporting systems and procedures as it integrates potential future
acquisitions. There can be no assurance that the Company will be able to
do so effectively, and failure to do so when necessary would have a
material adverse effect upon the Company's business and results of
operations. See "Management's Discussion and Analysis of Financial
Condition and Results of Operations."
RAPID TECHNOLOGICAL CHANGE; PRODUCT DEVELOPMENT. The market for the
Company's products is characterized by rapid technological advances,
changes in customer requirements and frequent new product introductions
and enhancements. The Company's future success will depend upon its
ability to enhance its current products, to develop and introduce new
products that keep pace with technological developments and to respond to
evolving customer requirements. Any failure by the Company to anticipate
or respond adequately to technological developments by its competitors or
to changes in customer requirements, or any significant delays in product
development or introduction, could result in a loss of competitiveness or
revenues. In the past, the Company has occasionally experienced delays in
the development and introduction of new products and product enhancements,
and there can be no assurance that the Company will not experience such
delays in the future. In addition, new product introductions or
enhancements by the Company's competitors or the use of other technologies
that do not depend on film digitization could cause a decline in sales or
loss of market acceptance of the Company's products. In particular,
direct capture computed radiography ("CR") systems are currently available
and have been sold for medical applications for over ten years with
limited acceptance. In addition, several companies have announced
developments in a technology leveraging the technology used in flat panel
displays to produce high-resolution, two dimensional image sensor arrays
that make it possible for x-ray images to be captured digitally without
film or chemical processing. Although this technology is not yet
commercially available, there can be no assurance that future advances in
this technology or other technologies will not produce systems better
positioned for the marketplace that will therefore reduce the digitizer
market to the then installed base of imaging systems. There can be no
assurance that the Company will be successful in developing and marketing
new products or product enhancements on a timely or cost-effective basis,
and such failure could have a material adverse effect on the Company's
business and results of operations. See "Business - Products and
Applications" and "- Research and Development."
COMPETITION. Although to date competition in the United States laser-
based film digitizer market has not been significant, a new company,
Clinical Laser Systems ("CLS") entered the market in 1996 with a product
similar to the laser-based film digitizers offered by Lumisys. In
additional, several Japanese competitors, such as Konica Corporation
("Konica"), Nishimoto Sangyo Co., Ltd. ("Nishimoto Sangyo") and Abe Sekkei
Inc. ("Abe Sekkei"), offer competitive products on an international basis
and may decide in the future to devote additional resources to marketing
competitive products in the United States. The markets for medical film
digitizers incorporating charge-coupled devices ("CCDs") are highly
competitive. The Company faces competition from companies such as Vidar
Systems Inc., Canon Inc., Vision Ten Inc., Hell Linotype and Howtek in the
CCD-based film digitizer market. There can be no assurance that the
Company's competitors will not develop enhancements to, or future
generations of, competitive products that will offer superior price or
performance features that render the Company's products less competitive
or obsolete.
In addition, large domestic companies, such as Kodak, Minnesota Mining &
Manufacturing Co. ("3M"), Sterling Diagnostics ("Sterling", formerly the
medical group of E.I. DuPont de Nemours and Company) and General Electric
Co. ("GE"), and European companies, such as Siemens, Philips Electronics
N.V. ("Philips") and Agfa, have the technical and financial ability to
design and market digitizer products competitive with the Company's
products, and some of them have in the past produced and marketed such
products. While most of these companies currently purchase products from
the Company, the Company believes that it will be required to continue to
improve the price and performance characteristics of its products to
retain their business especially in view of the fact that these customers
are not contractually required to purchase their digitizers exclusively or
at all from the Company. All of these companies have significantly
greater financial, marketing and manufacturing resources than the Company
and would be significant competitors if they decided to enter this market.
The markets for medical video image digitizers are also highly
competitive. Competitors in the video digitizer market are Precision
Digital Images Corp., Epix, Inc., Hell Linotype and Matrox Electronic
Systems Ltd. See "Business - Competition."
CUSTOMER CONCENTRATION; RELIANCE ON OEMs. A significant portion of the
Company's net sales is derived from a small number of customers. For the
period indicated, each of the following customers account for more than
10% of the Company's revenues: in 1994, E-Med, Eastman Kodak Company
("Kodak"), CEMAX-ICON, Inc. ("CEMAX-ICON") and Agfa Gavaert N.V. ("Agfa");
and in 1995, E-Med, Kodak and CEMAX-ICON. In 1996, Kodak, E-med and
CEMAX-ICON also accounted for a significant portion of the Company's net
sales although none accounted for more than 10%. Large customers also
accounted for a significant portion of the Company's backlog at December
31, 1996. The Company expects to continue to depend upon its principal
customers for a significant portion of its sales, although there can be no
assurance that the Company's principal customers will continue to purchase
products and services from the Company at current levels, if at all. The
loss of one or more major customers or a change in their buying patterns
could have a material adverse effect on the Company's business and results
of operations. See "Business - Sales and Marketing" and
"- Manufacturing."
SINGLE-SOURCE SUPPLIERS. The Company purchases industry-standard parts
and components for the assembly of its products, generally from multiple
vendors. Although the Company relies on single-source suppliers for
certain components, such as lasers, photomultiplier tubes and certain
electronic components primarily to control price and quality, the Company
believes that alternate sources of supply are available from other vendors
for such components and has qualified second source suppliers for some,
but not all, single-sourced parts. The Company maintains good
relationships with its vendors and, to date, has not experienced any
material supply problems. While the Company seeks to maintain an adequate
inventory of single-sourced components there can be no assurance that such
inventories will be sufficient or that delays in part or component
deliveries will not occur in the future, which could result in delays or
reductions in product shipments. Furthermore, even if currently single-
sourced components could be replaced by other qualified parts, product
redesign and testing could be costly and time consuming. These factors
could have a material adverse effect on the Company's business, financial
condition and results of operations.
GOVERNMENT REGULATION. The manufacturing and marketing of the Company's
digitizer and video board products are subject to extensive government
regulation in the United States and in other countries, and the process of
obtaining and maintaining required regulatory approvals is lengthy,
expensive and uncertain. If a medical device manufacturer can establish
that a newly developed device is "substantially equivalent" to a device
that was legally marketed prior to May 1976, the date on which the Medical
Device Amendments of 1976 were enacted, or to a device the FDA found to be
substantially equivalent to a legally marketed pre-1976 device, the
manufacturer may seek marketing clearance from the FDA to market the
device by filing a 510(k) premarket notification. The 510(k) premarket
notification must be supported by appropriate data establishing the claim
of substantial equivalence to the satisfaction of the FDA. Receipt of
510(k) clearance normally takes at least three months, but may take much
longer and may require the submission of clinical safety and efficacy data
to the FDA. All of the Company's laser-based film digitizers, the CCD-
based film digitizer and the QR2000 software products that are
commercially available have received 510(k) clearance. There can be no
assurance that 510(k) clearance for any future product or any modification
of an existing product will be granted, or that the process will not be
unduly lengthy. In the future, the FDA may require manufacturers of
certain medical devices to engage in a more thorough and time consuming
approval process than the 510(k) process, which could have a material
adverse effect on the Company's business and results of operations.
International sales of the Company's products may be subject to regulation
in various countries. The regulatory review process varies from country
to country and there can be no assurance that the Company will be able to
obtain foreign approvals on a timely basis or at all.
The Company is also required to register as a Class II medical device
manufacturer with the FDA and state agencies, such as the California
Department of Health Services ("CDHS"). As such, the Company may be
inspected on a routine basis by both the FDA and the CDHS for compliance
with the FDA's GMP and other applicable regulations. These regulations
require that the Company manufacture its products and maintain its
documents in a prescribed manner with respect to manufacturing, reporting
of product malfunctions and other matters. If the FDA believes that a
company is not in compliance with federal regulatory requirements, it can
institute proceedings to detain or seize products, issue a recall,
prohibit marketing and sales of the company's products and assess civil
and criminal penalties against the company, its officers or its employees.
Failure to comply with the regulatory requirements could have a material
adverse effect on the Company's business and results of operations. The
Company was inspected by the FDA in 1996 and was found to be compliant
with the FDA's GMP regulations but has not been inspected by CDHS to date.
THIRD-PARTY REIMBURSEMENT. Third-party payers, such as governmental
programs and private insurance plans, can indirectly affect the pricing or
the relative attractiveness of the Company's products by regulating the
maximum amount of reimbursement that they will provide for the taking,
storing and interpretation of medical images. In recent years, healthcare
costs have risen substantially, and third-party payers have come under
increasing pressure to reduce such costs. In this regard, extensive
studies undertaken by the Clinton Administration, even though not
successfully translated into regulatory action, have stimulated widespread
analysis and reaction in the private sector focused on healthcare cost
reductions, which may involve reductions in reimbursement rates in
radiology. A decrease in the reimbursement amounts for radiological
procedures may decrease the amount which physicians, clinics and hospitals
are able to charge patients for such services. As a result, adoption of
teleradiology and PACS may slow as capital investment budgets are reduced,
and the demand for the Company's products could be significantly reduced.
PRODUCT LIABILITY AND INSURANCE. The manufacture and sale of medical
products entails significant risk of product liability claims. While the
Company believes that its current insurance coverage is appropriate, there
can be no assurance that such coverage is adequate to protect the Company
from any liabilities it might incur in connection with the sale of the
Company's products. In addition, the Company may require increased
product liability coverage as additional products are commercialized.
Such insurance is expensive and in the future may not be available on
acceptable terms, if at all. A successful product liability claim or
series of claims brought against the Company in excess of its insurance
coverage could have a material adverse effect on the Company's business
and results of operations.
Item 1 BUSINESS
GENERAL
EXCEPT FOR THE HISTORICAL INFORMATION CONTAINED HEREIN, THE FOLLOWING
DISCUSSION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND
UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS COULD DIFFER MATERIALLY FROM
THOSE DISCUSSED HERE. FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH
DIFFERENCES INCLUDE, BUT ARE NOT LIMITED TO, THOSE DISCUSSED IN THIS
SECTION, AS WELL AS IN THE SECTIONS ENTITLED "RISK FACTORS" AND
"MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS," AND THOSE DISCUSSED IN OTHER REPORTS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.
Lumisys designs, manufactures and markets a family of precision digitizers
that convert medical images on film or video into digital format. Once in
digital form, the medical images can be stored, transmitted, viewed,
enhanced, manipulated and printed at any PC or workstation within a
medical network. The Company currently offers a comprehensive family of
products for digitizing medical film images under the Lumiscan label and
video images under the Imascan label. These digitizers process images
from all commercially available medical imaging modalities, including x-
ray, computed tomography ("CT"), magnetic resonance imaging ("MRI"),
ultrasound and nuclear medicine. The Company is the leading supplier of
laser-based film digitizers, with sales of approximately 3,000 Lumiscan
units since its first product was introduced in 1990, and has recently
introduced a CCD-based digitizer. The Company also offers high quality
board-level digitization and compression products for the capture of video
images, which have applications in medical imaging as well as in
scientific and industrial inspection and multimedia imaging.
In 1996, the Company introduced a computed radiography ("CR") system for
use in the industrial inspection market. The CR system reads images from
reusable phosphor plates of pipes, valves, aircraft parts and other
structural objects.
Also in 1996, the Company purchased QR2000 software technology and is
continuing the development of the product. QR2000 is an efficiency tool
for use in an ultrasound department. The product allows simultaneous
viewing of up to nine ultrasound rooms from a single station. The
ultrasound images can be captured and read from the QR2000 system thereby
saving time and film costs.
Lumisys intends to maintain and enhance its market leadership by
leveraging its reputation for high quality, reliable and cost-effective
products, broadening its product lines through internal product
development, acquiring complementary businesses or technologies and
penetrating new geographic markets. The Company sells its products
primarily to OEMs and VARs, who then integrate the Company's products into
teleradiology and Picture Archiving and Communication Systems ("PACS")
networks. Lumisys has established close working relationships with the
leading suppliers of these systems including Agfa, CEMAX-ICON, E-Med, GE,
Kodak, Philips and Sterling Diagnostics.
INDUSTRY BACKGROUND
The use of medical film images to diagnose and treat diseases and injuries
has been an important medical tool since the invention of x-ray technology
and the emergence of radiology as a medical specialty. Today,
radiologists review and interpret images from a variety of imaging
modalities, including x-rays, CT, MRI, ultrasound and nuclear medicine.
These modalities are used in a range of different applications requiring
specialized equipment to produce images on film or video displays.
Medical imaging has reduced the need for exploratory surgical procedures
and has enabled clinicians to make faster and more precise diagnoses and
prescribe more targeted courses of treatment. Medical imaging is used in
all stages of the patient management cycle, from screening to diagnosis,
treatment and post-treatment assessment. In 1992, according to an
industry source, approximately $1 billion of medical film was consumed in
the United States as a result of radiographic and fluoroscopic studies
performed, CT scans, MRI scans and nuclear medicine examinations.
The healthcare industry in the United States continues to change
dramatically in response to the escalating costs associated with medical
products and services. An increased emphasis on lowering costs and
optimizing resources has encouraged the healthcare industry to evolve
toward managed regional healthcare systems. These changes in the
healthcare industry are having a profound impact on the practice of
radiology. In the past, radiologists were located in a medical facility
close to the patient where they performed examinations and interacted
face-to-face with the local clinician and the patient. As reimbursement
for radiological interpretations have declined, radiologists are under
pressure to increase the number of interpretations and compete for
business over much larger geographic areas. In addition, with the
development of advanced medical imaging technologies, radiologists have
been able to sub-specialize, becoming, for example, neuroradiologists,
mammographers, orthopedic radiologists, angiographers or pediatric
radiologists. The evolution toward managed regional healthcare systems
and increasing radiologist specialization have resulted in a need to
develop equipment and systems capable of transmitting medical images
rapidly to and from remote locations.
Concurrent with these changes in radiology, the computing and
telecommunications industries have experienced rapid growth and
technological advancements. Today, high-quality medical images can be
transmitted over broadband communications networks. Recent trends in the
healthcare market to lower costs and optimize resources combined with the
rapid growth of digital communications networks have accelerated the
acceptance of teleradiology, the practice of radiology from remote
locations. In teleradiology, medical images at the point of care are
digitized and transmitted to central locations for interpretation,
bringing the patient's information to the radiologist faster and at
significantly lower cost than the traditional method of transporting the
patient from the point-of-care facility to the diagnostic facility.
In addition, the digitization and transmission of medical images has
enabled the formation of large scale image storage and management networks
known as PACS. PACS combine teleradiology and medical information systems
to facilitate (i) the management of medical images from various imaging
modalities, (ii) the storage and retrieval of the images in large
electronic archives, (iii) the manipulation and enhancement of such images
for display at any time and at any workstation in the network and (iv) the
integration of radiological information into existing patient management
systems and hospital information systems. PACS, typically found in large
regional hospitals and university research centers, minimize the risk of
loss of the master image and reduce the overall costs of providing
efficient radiology services. It is estimated that approximately 10% of
all medical films are lost and an additional 10% to 15% are misplaced or
misfiled, creating the need to take expensive duplicate images, delaying
the delivery of quality medical care and resulting in increased medical
costs.
Increased adoption of teleradiology and PACS is currently occurring among
healthcare providers in response to pressures to create a more efficient
healthcare delivery system in the United States, Canada, Western Europe,
Japan and Australia. In addition, many countries in South America and
Asia are focusing on providing better healthcare and are investing in CT,
MRI and other modern imaging modalities. The Company believes that these
countries present potential opportunities for the implementation of
teleradiology systems.
STRATEGY
Lumisys is a leading suppler of digitizers for medical film and video
images and has established a reputation for delivering high-quality,
reliable and cost-effective products. The Company intends to leverage
this reputation by broadening its product line, exploiting new market
opportunities and penetrating new geographic markets. The Company's
strategy includes the following key elements:
APPLY CORE TECHNOLOGICAL COMPETENCIES TO DEVELOP NEW PRODUCTS. Lumisys
has developed expertise in electro-optics, image processing, circuit
design, computing, software and communications for image digitization.
The Company's strategy is to provide increased functionality, application-
specific software and additional components to enhance its core product
line and address emerging market needs.
ACQUIRE COMPLEMENTARY PRODUCTS AND TECHNOLOGY. The Company intends to
continue to identify and acquire complementary businesses, products and
technologies that offer Lumisys the ability to introduce new products, add
core technological competencies and leverage existing strengths to provide
better solutions for its target markets. In early 1996, the Company
acquired the QR2000 product to add core technical competencies in software
development and to leverage its existing strong OEM and VAR relationships
in the medical imaging market. In 1995, the Company acquired X-Ray
Scanner Corporation ("XRS") to accelerate its development of a lower cost
CCD-based film digitizer line and acquired Imagraph Corporation
("Imagraph") to add core technical competencies in video image
digitization and compression.
EXPLOIT MARKET OPPORTUNITIES THROUGH STRONG OEM RELATIONSHIPS. The
Company has established strong relationships with the key suppliers of
medical image management products and systems. These relationships
provide the Company with insight into emerging customer requirements,
which allows the Company to position its current products appropriately
and to allocate more effectively its product development resources. In
addition, as OEM customers increasingly outsource parts and components for
their systems, Lumisys intends to take advantage of its strong OEM
relationships and its reputation for high-quality products to remain the
supplier of choice with an expanding product line.
PENETRATE NEW GEOGRAPHIC MARKETS. The Company believes that significant
opportunities exist for international expansion, primarily in Canada,
Western Europe, Japan and Australia. In addition, many countries in South
America and Asia are focusing on providing better healthcare and are
investing in CT, MRI and other modern imaging modalities. The Company
believes that these countries present potential opportunities for the
implementation of teleradiology systems. The Company intends to identify
specific market dynamics in these foreign countries and design targeted
products and systems for their medical imaging needs. The Company's
development of a lower cost CCD-based film digitizer was the first step
toward addressing some of the needs of these markets. In 1996, Lumisys
acquired a simplistic teleradiology software package that is intended to
be sold with the CCD-based digitizer to provide a basic teleradiology
system. The Company believes that the basic system is particularly well
suited to customers in developing countries where price is a more
important factor than in the United States. These customers could then
upgrade to the Company's laser-based digitizer products and the Company's
OEM customer's more sophisticated software systems as their needs
increase.
PRODUCTS AND APPLICATIONS
The Company currently offers a comprehensive family of products for
digitizing medical film and video images from all commercially available
medical imaging modalities. Lumisys digitizers enable the conversion of
analog medical images into the digital format required by integrated
teleradiology systems. In a typical teleradiology application, a film or
video image is digitized into a host computer using a Lumisys digitizer.
The digitized film may be transmitted over telephone line, dedicated high-
speed communication lines or satellite links and may be compressed to
reduce transmission time. In a typical PACS network, current or
previously archived medical images from a variety of imaging modalities
and other patient information are transmitted over local and wide area
networks ("LAN/WAN"). The Company's digitizers make possible the entry of
medical images into PACS networks.
LUMISCAN PRODUCTS. The Lumiscan family consists of a full line of laser-
based scanning medical film densitometers, primarily used for x-ray film
digitization. These digitizers incorporate lasers, precision optics,
computer-controlled galvanometers and micropositioners, special purpose
light detectors and analog as well as digital electronic circuitry. The
Lumiscan product line also includes a CCD-based film digitizer that
incorporates a proprietary light source and a high quality CCD detector.
In addition, the Lumiscan product line includes a CR system that
incorporates much of the same technology and manufacturing techniques as
the other digitizers. CR uses specialized phosphor plates to capture an
x-ray image instead of film. All Lumiscan digitizers include
sophisticated proprietary control software as well as internally developed
input/output and driver software.
The Lumiscan 50 and 75, introduced in 1993 and 1994, respectively, utilize
a common housing and are light weight, tabletop units. The Lumiscan 50 is
a lower resolution product that is used primarily in non-diagnostic
teleradiology applications. The Lumiscan 75 is a higher resolution
product designed for diagnostic teleradiology. The Lumiscan 85 is
designed specifically to capture information from x-ray mammograms,
pediatric images and in non-destructive test applications. The Lumiscan
85 offers very high resolution allowing it to capture the wide dynamic
range and requisite image information contained in these images, which are
generally smaller and require a higher optical density to diagnose
effectively.
The Lumiscan 150 and 200 utilize larger housings than the Lumiscan 50, 75
and 85 and are designed for PACS applications. These models are quickly
being displaced by the less expensive desktop models. The Lumiscan 150
was introduced in 1992. The Lumiscan 200, introduced in 1991, is equipped
with a film feeder capable of automatically digitizing up to 70 sheets of
film, increasing operator productivity in high-volume PACS environments.
The Lumiscan 100 was the Company's first product, introduced in 1990, and
has been superseded by the Company's other Lumiscan products for most
applications. The Lumiscan 100 is still commercially available and is
used primarily by large research universities because of its high
precision, variable resolution capabilities and ability to accommodate a
broad range of film sizes.
The Company began shipping the Lumiscan 20 tabletop film digitizer, which
is based on CCD technology, in January, 1996. The Lumiscan 20 is a less
expensive film digitizer designed for use in less demanding applications
and environments, where price is a more important factor than resolution.
The Company designed the Lumiscan 20 to be cost-competitive, to exhibit
superior image quality over CCD-based products offered by its competitors
and to include an optional film feeder. The Company received FDA 510(k)
clearance for the Lumiscan 20 in the fourth quarter of 1995.
The Company introduced the Lumiscan 110 CR system in 1996. The CR system
was designed specifically to capture information from storage phosphors
rather than film. These digitizers are being used for filmless radiograph
applications in the non-destructive test ("NDT") market. Inspection of
pipes, valves, aircraft parts and other structural objects can be
accomplished without the use of conventional silver halide emulsion
radiographic films. These digitizers are similar in size and weight to
the other Lumisys tabletop digitizers.
BOARD PRODUCTS. Lumisys also develops, manufactures and markets high-
quality, board-level digitization and compression products for the capture
of video images. These digital images can be reproduced on workstations
and displays, transmitted over networks, recorded into archives and
accurately reprinted. These products have applications in medical imaging
as well as in scientific and industrial inspection and multimedia imaging.
They incorporate programmable gate-arrays, embedded signal processors,
proprietary software and double-sided, surface-mounted technology.
Additionally, the Company's proprietary Auto-Sync software automatically
adjusts to accommodate the variety of video signals to be digitized. This
capability allows the Company's OEM and VAR customers to install these
products without having to develop extensive video installation expertise
or to acquire special test equipment.
The HI*DEF Plus is a standard PC-compatible board that digitizes analog
video images at up to 140 MHz sampling rates with continuous Auto-Sync
locking circuitry to maintain image fidelity at optimum signal-to-noise
ratios. This product is primarily used to digitize video from CT, MRI,
ultrasound and nuclear medicine cameras in medical applications as well as
from high resolution video cameras used for industrial inspection and
quality control applications.
The Company also offers the Imascan line of monochrome and color video
frame grabbers with SVGA display capabilities on a single board. These
PCI boards have applications in medical ultrasound imaging as well as
graphic arts, desktop video and the teleconference markets. Imascan
Precision is the most recent addition to this family and integrates the
most advanced features offered by this product line.
In the fourth quarter of 1996, the company introduced its integrated
compression engine known as I.C.E. Clarity. This computer board can
compress or decompress images at a speed greater than thirty images per
second. When used in a multitasking operating system such as Windows NT,
lossless JPEG compression/decompression operations can be accomplished in
real-time while consuming very little computer processing bandwidth.
Applications for this product have been initially targeted for capturing,
reviewing and archiving medical images from cardiology workstations.
RESEARCH AND DEVELOPMENT
Lumisys devotes significant resources to research and development
activities to design new products and product enhancements and identify
new applications for existing products. The Company has developed
expertise in electro-optics, image processing, circuit design, computing,
software and communications for image digitization, which the Company
believes it can leverage to introduce new products and product
enhancements. The Company's engineers work closely with its OEM and VAR
customers to assist in the integration of the Company's products with
those of the OEMs and VARs and to identify new applications for the
Company's products. Occasionally, the Company receives funding from
certain OEM and VAR customers to develop specialized applications.
For the years 1996, 1995 and 1994, the Company's research and development
expenditures were approximately $4.1 million, $2.9 million (not including
a charge of $1.4 million for acquisition of in-process research and
development) and $1.5 million, respectively. These amounts represented
18.0%, 16.7% and 17.0% of total revenues in the respective periods. In
1996, research and development resources were used primarily for the
development of the CR system (the Lumiscan 110) and the integrated
compression engine ("ICE") product which were introduced in 1996, as well
as for the continuing development of the QR2000 ultrasound workstation
tool.
As of December 31, 1996, the Company had 28 employees engaged in research
and development activities.
SALES AND MARKETING
The Company sells its film digitizers primarily to OEM and VAR customers
who integrate these products into teleradiology and PACS networks. The
Company also sells its film digitizers to a few end users, primarily
university and medical research groups. The Company's video image
digitizers are sold to many of these same customers as well as to dealers,
distributors and resellers for medical, multimedia, scientific and
industrial applications.
The Company markets its products primarily through an internal sales
organization. In addition, the Company exhibits its products at major
trade shows and supports the OEMs, VARs, dealers, distributors and
resellers with product literature and application notes for reference and
distribution. The Company maintains a staff of 11 sales and marketing
personnel, with three individuals responsible for film digitizer products,
six individuals responsible for video image digitizers, one individual
responsible for software products and one individual responsible for new
business development. All of the sales personnel are supported by a
technical support organization and the engineering staff is available to
support the Company's customers when appropriate. The Company devotes a
substantial portion of its marketing efforts to developing, monitoring and
enhancing its relationships with existing customers and to identifying and
cultivating new customers entering the market. The loss of one or more
customers or a change in their buying pattern could have a material effect
on the Company's business and results of operations.
The Company emphasizes customer service and support by developing quality
products, encouraging customer feedback through extensive contacts with
key OEM and VAR customers, maintaining accurate documentation of technical
support requests and providing customers with telephone support. The
technical support staff conducts a film digitizer service training course
for OEM and VAR personnel on a regular basis, providing the Company's
customers with the expertise needed to install and support the Company's
products. The Company provides a limited one-year parts or factory repair
warranty to end-user customers, which can be performed by either the end
customer or the OEMs or VARs service personnel once installation has been
completed. Although the Company's warranty policy permits the customer to
return the product in the event of malfunction, product returns to date
have been insignificant.
MANUFACTURING
The Company's manufacturing activities consist primarily of assembling and
testing components and subassemblies acquired from qualified vendors as
well as assembling, aligning, system testing and performing quality
assurance inspection of the end product . The Company's film digitizer
facility operates under the FDA GMP guidelines and is a registered medical
device manufacturer.
The Company purchases industry-standard parts and components for the
assembly of its products, generally from multiple vendors. Although the
Company relies on single-source suppliers for certain components, such as
lasers, photomultiplier tubes and certain electronic components primarily
to control price and quality, the Company believes that alternate sources
of supply are available from other vendors for such components and has
qualified second source suppliers for some, but not all, single-sourced
parts. The Company maintains good relationships with its vendors and, to
date, has not experienced any material supply problems.
The Company's backlog at December 31, 1996 was approximately $4.2 million
compared with $3.5 million at December 31, 1995. The Company includes in
its backlog only orders for which a customer purchase order has been
received and a delivery date within six months has been specified.
COMPETITION
Although competition in the United States laser-based film digitizer
market currently is not significant, several Japanese competitors such as
Konica, Nishimoto Sangyo and Abe Sekkei offer competitive products on an
international basis and may decide in the future to devote additional
resources to marketing competitive products in the United States. In both
the film and the video image digitizer market segments, significant
competitive factors include product functionality, performance, cost,
market presence, installed base, customer satisfaction, customer support
capabilities and breadth of product line. The Company believes that it
competes favorably on the basis of each of these factors.
The Company competes in a rapidly advancing field of technology in which
its ability to compete depends upon the continuing improvement of its
products, cost reductions and the development of new products to meet
changing customer requirements. New advances in technology have produced
imaging systems capable of generating digital images without the need for
some of the Company's products. In particular, CR systems are currently
available and have been sold for medical applications for over ten years
with limited acceptance. In addition, several companies have announced
developments in a technology leveraging the technology used in flat panel
displays to produce high-resolution, two dimensional image sensor arrays
that make it possible for x-ray images to be captured digitally without
film or chemical processing. While Flat-panel technology is just being
announced commercially there are potential issues with both cost and image
quality. The Company cannot predict whether such technology will gain
market acceptance or provide increased competition to the Company's
products.
As a result of the substantial investment required by an OEM or VAR
customer to integrate capital equipment into a production line, or to
integrate components and subsystems into a product design, the Company
believes that once an OEM or VAR customer has selected certain capital
equipment or certain components or subsystems from a particular vendor,
the customer generally relies upon that vendor to provide equipment for
the specific production line or product application and may seek to rely
upon that vendor to meet other component or subsystem requirements.
Accordingly, the Company may be at a competitive advantage or disadvantage
with respect to a particular customer depending on whether that customer
utilizes the Company's or a competitor's component or subsystem.
PATENTS AND INTELLECTUAL PROPERTY
The Company believes that the success of its business depends more on the
technical competence and creativity of its employees and successful
business execution than on patents, trademarks and copyrights. Although
the Company has obtained several patents it generally does not rely
primarily on patent protection with respect to its products. As of
January 31, 1997, the Company held or had a license to eleven United
States patents, expiring between 2010 and 2014.
Competitors in the United States and foreign countries, many of which have
substantially greater resources and have made substantial investments in
competing technologies, may have applied for or obtained, or may in the
future apply for and obtain, patents that may prevent, limit or interfere
with the Company's ability to make and sell some of its products.
Although the Company believes that its products do not infringe the
patents or other proprietary rights of third parties, there can be no
assurance that third parties will not assert infringement claims against
the Company or that such claims will not be successful.
The Company also relies upon trade secret protection for its confidential
and proprietary information. The Company routinely enters into
confidentiality agreements with its employees, consultants and customers
who have access to the Company's confidential or proprietary information.
It is not clear, however, that these agreements will provide meaningful
protection of the Company's trade secrets, know-how or other proprietary
information in the event of any unauthorized use, misappropriation or
disclosure of such trade secrets, know-how or other proprietary
information.
GOVERNMENT REGULATION
The manufacturing and marketing of the Company's digitizer and video board
products are subject to extensive government regulation in the United
States and in other countries, and the process of obtaining and
maintaining required regulatory approvals is lengthy, expensive and
uncertain. All of the Company's laser-based film digitizers, the CCD-
based film digitizer and the QR2000 software products that are
commercially available have received marketing clearance from the FDA via
a 510(k) filing. International sales of the Company's products may be
subject to regulation in various countries. The regulatory review process
varies from country to country. To date, the Company's revenue has not
been adversely impacted by an inability to obtain domestic or foreign
marketing clearances.
The Company is also required to register as a Class II medical device
manufacturer with the FDA and state agencies, such as the California
Department of Health Services ("CDHS"). As such, the Company may be
inspected on a routine basis by both the FDA and the CDHS for compliance
with the FDA's GMP and other applicable regulations. These regulations
require that the Company manufacture its products and maintain its
documents in a prescribed manner with respect to manufacturing, reporting
of product malfunctions and other matters. The Company was inspected by
the FDA in 1996 and was found to be compliant with the FDA's GMP
regulations but has not been inspected by CDHS to date.
Item 2. PROPERTIES
The Company's principal facilities are located in Sunnyvale, California
and Chelmsford, Massachusetts. Corporate headquarters are located in the
Sunnyvale facility, an approximately 25,000 square foot facility leased
through December 2000. The Chelmsford facility, which houses the Imagraph
subsidiary, is located in an approximately 17,000 square foot building
leased through June 1997. The Company believes that it will be able to
find suitable alternate facilities in the same general area without a
material disruption of its Massachusetts-based operations.
Item 3. LEGAL PROCEEDINGS
None.
Item 4. SUBMISSION OF MATTERS TO A VOTES OF SECURITIES HOLDERS
None.
PART II.
Item 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED
STOCHOLDER MATTERS
The Company's Common Stock commenced trading on the Nasdaq National Market
on November 15, 1995, under the symbol LUMI. As of February 11, 1997,
there were approximately 189 shareholders of record.
The following table sets forth for the periods indicated, the high and low
closing sale prices of the Company's Common Stock.
High Low
Fiscal 1996 Fourth Quarter $12.25 $ 9.38
Third Quarter $15.50 $ 8.38
Second Quarter $28.63 $13.63
First Quarter $22.63 $10.00
Fiscal 1995 Fourth Quarter $11.25 $ 7.25
Lumisys has never paid dividends on its Common Stock and does not
anticipate paying cash dividends in the future.
Item 6. SELECTED FINANCIAL DATA
The following selected consolidated financial data should by read in
conjunction with "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and the Consolidated Financial
Statements and the Notes thereto included elsewhere in this report. The
consolidated statement of operations data for the years ended December 31,
1996, 1995 and 1994 and the consolidated balance sheet data at December
31, 1996 and 1995 are derived from, and should be read in conjunction with
the Company's consolidated financial statements and Notes thereto audited
by Price Waterhouse LLP, independent accountants, included elsewhere in
this report. The consolidated statement of operations data for the years
ended December 31, 1993 and 1992 and the consolidated balance sheet data
at December 31, 1994, 1993 and 1992 are derived from the Company's audited
consolidated financial statements not included in this report.
Year ended December 31,
----------------------------------------
1996 1995 1994 1993 1992
------- ------- ------ ------ ------
(in thousands, except per share data)
Consolidated Statement of Operations Data:
Sales $23,022 $17,662 $8,807 $6,180 $6,436
Cost of sales 10,505 8,228 4,042 2,809 2,910
------- ------- ------ ------ ------
Gross profit 12,517 9,434 4,765 3,371 3,526
------- ------- ------ ------ ------
Operating expenses:
Sales and marketing 1,949 1,606 851 921 922
Research and development 4,145 2,946 1,496 1,295 940
General and administrative 2,238 1,832 712 414 650
Acquired in-process
research and development --- 1,442 --- --- ---
------- ------- ------ ------ ------
Total operating expenses 8,332 7,826 3,059 2,630 2,512
------- ------- ------ ------ ------
Income from operations (1) 4,185 1,608 1,706 741 1,014
Interest income, net 916 223 95 45 26
------- ------- ------ ------ ------
Income before income taxes 5,101 1,831 1,801 786 1,040
Provision (benefit) for
income taxes 1,662 (762) 95 10 ---
------- ------- ------ ------ ------
Net income (2) $ 3,439 $ 2,593 $1,706 $ 776 $1,040
======= ======= ====== ====== ======
Net income per share (2)(3) $ 0.50 $ 0.49 $ 0.34 $ 0.16 $ 0.22
Shares used to compute
net income per share (3) 6,829 5,305 4,998 4,888 4,793
December 31,
----------------------------------------
1996 1995 1994 1993 1992
------- ------- ------ ------ ------
(in thousands)
Consolidated Balance Sheet Data:
Cash, cash equivalents and
short-term investments $18,438 $15,360 $3,633 $2,276 $1,636
Working capital 24,145 19,188 4,571 2,857 2,023
Total assets 27,090 22,743 5,701 3,560 3,011
Mandatorily redeemable
convertible preferred stock --- --- 9,730 9,634 9,529
Retained earnings
(accumulated deficit) 918 (2,521) (5,114) (6,724) (7,395)
Stockholders' equity (deficit)24,663 19,750 (5,080) (6,695) (7,373)
- --------------------------------
(1) In March 1995, the Company recorded a one-time charge of $1,442,000
related to acquired in-process research and development. See Note 4 of Notes
to Consolidated Financial Statements.
(2) Excludes accretion of mandatorily redeemable convertible preferred stock.
(3) See Note 2 of Notes to Consolidated Financial Statements for a description
of the shares used in calculating net income per share.
Item 7. MANAGMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
OVERVIEW
Lumisys designs, manufactures and markets a family of precision digitizers
that convert medical images on film or video into digital format. The
Company's first product, the Lumiscan 100, was introduced in 1990.
Subsequently, the Company has introduced a new Lumiscan model every year.
Substantially all of the Company's sales are derived from medical image
digitizers and replacement parts to OEMs and VARs who integrate these
products into teleradiology and PACS networks.
In March 1996, the Company acquired the QR2000 product to add core
technical competencies in software development. In 1995, the Company
acquired XRS to accelerate the development of a CCD-based film digitizer
line and Imagraph to add core technical competencies in video image
digitization and compression. The Company recorded a write-off
aggregating $1.4 million for acquired in-process research and development
associated with the 1995 acquisitions. The Company intends to continue to
identify and acquire complementary businesses, products and technologies
to broaden its product lines and enter new markets. Such acquisitions may
result in potentially dilutive issuances of equity securities, the
incurrence of debt, one-time acquisition charges and amortization expenses
related to goodwill and intangible assets, each of which could adversely
affect the Company's financial condition and results of operations.
Except for the historical information contained herein, the following
discussion contains forward-looking statements that involved risks and
uncertainties. The Company's actual results could differ materially from
those discussed here. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed in this
section, as well as in the sections entitled "Risk Factors" and
"Business," and those discussed in the other documents filed by the
Company with the Securities and Exchange Commission.
RESULTS OF OPERATIONS
The following table sets forth, for the periods indicated, certain
statement of operations data as a percentage of sales:
Year ended December 31,
-----------------------
1996 1995 1994
------- ------- -------
Sales 100.0% 100.0% 100.0%
Cost of sales 45.6 46.6 45.9
------- ------- -------
Gross profit 54.4 53.4 54.1
------- ------- -------
Operating expenses:
Sales and marketing 8.5 9.1 9.6
Research and development 18.0 16.7 17.0
General and administrative 9.7 10.4 8.1
Acquired in-process research
and development --- 8.2 ---
------- ------- -------
Total operating expenses 36.2 44.4 34.7
------- ------- -------
Income from operations 18.2 9.0 19.4
Interest income, net 4.0 1.3 1.0
------- ------- -------
Income before income taxes 22.2 10.3 20.4
Provision (benefit ) for
income taxes 7.2 (4.3) 0.1
------- ------- -------
Net income 15.0 14.6 19.4
======= ======= =======
FISCAL 1996 COMPARED WITH FISCAL 1995
SALES. Sales increased 30.3% in 1996 to $23.0 million from $17.7 million
in 1995. This increase was due in part to new products launched in 1996
and late 1995. The new products included the Lumiscan 20, a CCD-based
film digitizer developed with technology obtained in the XRS acquisition,
the Lumiscan 110, a computed radiography system used in industrial
inspection and the Lumiscan 85, a high end digitizer targeted for
mammography and non-destructive test applications. The remaining increase
in sales is a result of growth in demand for teleradiology and PACS
networks. In 1996, no customers accounted for more than 10% of the
Company's sales compared to three customers accounting for 10% or more of
the Company's sales in 1995.
GROSS PROFIT. Gross profit increased 32.7% in 1996 to $12.5 million from
$9.4 million in 1995. Gross margin increased from 53.4% to 54.4%
primarily due to increased sales which improved absorption of
manufacturing overhead.
SALES AND MARKETING. Sales and marketing expenses increased in 1996 to
$1.9 million from $1.6 million in 1995, primarily due to the increase in
the Company's sales and marketing personnel. As a percentage of sales,
these expenses decreased to 8.5% in 1996 from 9.1% in 1995. Because the
Company's distribution channels rely on established OEM and VAR customers,
which generally provide sales and field support for the products, the
Company does not need to increase sales and support personnel
proportionately with increases in sales. However, the Company anticipates
that additional resources will be required as the Company expands both its
customer and geographic bases.
RESEARCH AND DEVELOPMENT. Research and development expenses increased in
1996 to $4.1 million from $2.9 million in 1995, primarily due to increased
engineering. As a percentage of sales, research and development expenses
increased to 18.0% in 1996 from 16.7% in 1995. The Company believes that
advanced technology is a key element in the success of its business and
expects to continue to increase its research and development expenditures
in absolute dollar amounts.
GENERAL AND ADMINISTRATIVE. General and administrative expenses increased
in 1996 to $2.2 million from $1.8 million in 1995. The increase was
primarily due to the on-going costs associated with increased personnel
expenses as a result of being a public company. As a percentage of sales,
these expenses decreased to 9.7% in 1996 from 10.4% in 1995. The Company
expects that its general and administrative expenses will increase in
absolute dollars in the future as the Company expands its staffing to
support expanded operations.
PROVISION (BENEFIT) FOR INCOME TAXES. The Company recorded a current
provision for income taxes of $2.0 million in 1996 which was partially
offset by a deferred benefit of $315,000 resulting in a net provision of
$1.7 million. In 1995, the Company recorded a provision for income taxes
of $338,000 which was offset by the recognition of $1.1 million of
deferred tax assets, resulting in a net benefit of $762,000 for the year.
The recognition of deferred tax assets was based on the Company's
assessment that it is more likely than not that this portion of the
deferred tax assets will be realized. The Company has provided a partial
valuation allowance against the balance of the deferred tax assets. At
December 31, 1996, the Company had net operating loss carryforwards
available to reduce income taxes for federal and state income tax purposes
of approximately $800,000 and $500,000, respectively; such carryforwards
expire through 2007 but are substantially limited per year. In addition,
at December 31, 1996, the Company had research and development tax
carryforwards available to reduce income taxes for federal and state
income tax purposes of approximately $40,000 and $120,000 which expire
from 2004 to 2010. See Note 5 of Notes to Consolidated Financial
Statements. The Company expects to be subject to an effective tax rate of
approximately 39% in 1997, absent changes in any applicable statutory tax
rate.
FISCAL 1995 COMPARED WITH FISCAL 1994
SALES. Sales increased 100.5% in 1995 to $17.7 million from $8.8 million
in 1994. This increase was due in part to the acquisition of Imagraph
and XRS, which contributed $4.8 million and $405,000, respectively, or
approximately 29.4% of sales in 1995. Excluding the acquisitions, the
percentage increase in sales would have been 41.2%, primarily as a result
of growth in demand for teleradiology and PACS networks. In 1995, each of
three customers accounted for more than 10% of the Company's sales, as
they did in 1994.
GROSS PROFIT. Gross profit increased 98% in 1995 to $9.4 million from
$4.8 million in 1994. Gross profit as a percentage of sales declined from
54.1% to 53.4% primarily due to the lower gross profit margins associated
with the Imagraph video board products acquired in March 1995.
SALES AND MARKETING. Sales and marketing expenses increased in 1995 to
$1.6 million from $0.9 million in 1994, primarily due to the increase in
the Company's sales and marketing personnel as a result of the
acquisitions of Imagraph and XRS. As a percentage of sales, these
expenses decreased to 9.1% in 1995 from 9.6% in 1994. Because the
Company's distribution channels rely on established OEM and VAR customers,
which generally provide sales and field support for the products, the
Company does not need to increase sales and support personnel
proportionately with increases in sales.
RESEARCH AND DEVELOPMENT. Research and development expenses increased in
1995 to $2.9 million from $1.5 million in 1994, primarily due to increased
engineering personnel as a result of the acquisitions of Imagraph and XRS.
As a percentage of sales, research and development expenses decreased to
16.7% in 1995 from 17.0% in 1994.
GENERAL AND ADMINISTRATIVE. General and administrative expenses increased
in 1995 to $1.8 million from $0.7 million in 1994. The increase was due
in part to expenses incurred in anticipation of the acquisitions of
Imagraph and XRS and in part to the on-going costs associated with
increased personnel expenses following the acquisitions. As a percentage
of sales, these expenses increased to 10.4% in 1995 from 8.1% in 1994.
ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE. Acquired in-process
research and development expenses represent a non-recurring charge in 1995
of $1.4 million relating to products being developed by Imagraph and XRS
at the time of the acquisitions.
PROVISION (BENEFIT) FOR INCOME TAXES. The Company recognized a benefit
for income taxes of $762,000 in 1995 compared with a provision of $95,000
in 1994. The acquired in-process research and development expense is not
deductible for tax purposes, which resulted in significantly higher
alternative minimum taxes for 1995, offset by the recognition of $1.1
million of deferred tax assets, based on the Company's assessment that it
is more likely than not that this portion of the deferred tax assets will
be realized.
QUARTERLY RESULTS
The following table sets forth a summary of the Company's quarterly
operations data for each quarter of fiscal 1995 and 1996. This
information has been derived from the Company's unaudited quarterly
consolidated financial statements. In management's opinion, these
quarterly results have been prepared on a basis consistent with the
audited Consolidated Financial Statements contained elsewhere herein, and
include all adjustments, consisting only of normal recurring adjustments,
which the Company considers necessary for a fair presentation of the
information for the quarters presented. This data should be read in
conjunction with the Company's Consolidated Financial Statements and Notes
thereto appearing elsewhere in this report. The operating results for any
quarter are not necessarily indicative of results for any future period.
Quarter ended
-------------------------------------------------------
Mar.31,Jun.30,Sep.30,Dec.31,Mar.31,Jun.30,Sep.30,Dec.31,
1995 1995 1995 1995 1996 1996 1996 1996
------ ------ ------ ------ ------ ------ ------ ------
(in thousands)
Sales $2,404 $4,674 $5,013 $5,571 $5,110 $5,872 $5,933 $6,107
Cost of sales 1,068 2,191 2,322 2,647 2,395 2,716 2,684 2,710
------ ------ ------ ------ ------ ------ ------ ------
Gross profit 1,336 2,483 2,691 2,924 2,715 3,156 3,249 3,397
------ ------ ------ ------ ------ ------ ------ ------
Operating expenses:
Sales and
marketing 247 453 412 494 483 456 463 547
Research and
development 387 834 821 904 999 1,036 1,064 1,046
General and
administrative 266 516 540 510 628 584 622 404
Acquired in-process
research and
development 1,442 --- --- --- --- --- --- ---
------ ------ ------ ------ ------ ------ ------ ------
Total operating
expenses 2,342 1,803 1,773 1,908 2,110 2,076 2,149 1,997
------ ------ ------ ------ ------ ------ ------ ------
Income (loss)from
operations(1) (1006) 680 918 1,016 605 1,080 1,100 1,400
Interest
income, net 47 31 32 113 215 214 238 249
------ ------ ------ ------ ------ ------ ------ ------
Income (loss)
before income
taxes (959) 711 950 1,129 820 1,294 1,338 1,649
Provision (benefit)
for income taxes 54 (731) (47) (38) 98 398 522 644
------ ------ ------ ------ ------ ------ ------ ------
Net income
(loss)(1)(2) $(1,013)$1,442 $ 997 $1,167 $ 722 $ 896 $ 816 $1,005
======= ====== ====== ====== ====== ====== ====== =====
As a percentage of total sales:
Quarter ended
-------------------------------------------------------
Mar.31,Jun.30,Sep.30,Dec.31,Mar.31,Jun.30,Sep.30,Dec.31,
1995 1995 1995 1995 1996 1996 1996 1996
------ ------ ------ ------ ------ ------ ------ ------
Sales 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Cost of sales 44.4 46.9 46.3 47.5 46.9 46.2 45.2 44.4
------ ------ ------ ------ ------ ------ ------ ------
Gross profit 55.6 53.1 53.7 52.5 53.1 53.8 54.8 55.6
------ ------ ------ ------ ------ ------ ------ ------
Operating expenses:
Sales and
marketing 10.3 9.7 8.2 8.9 9.4 7.8 7.8 9.0
Research and
development 16.1 17.8 16.4 16.2 19.6 17.6 17.9 17.1
General and
administrative 11.0 11.1 10.8 9.2 12.3 10.0 10.5 6.6
Acquired in-
process research
and development 60.0 --- --- --- --- --- --- ---
------ ------ ------ ------ ------ ------ ------ ------
Total operating
expenses 97.4 38.6 35.4 34.3 41.3 35.4 36.2 32.7
------ ------ ------ ------ ------ ------ ------ ------
Income (loss) from
operations (1) (41.8) 14.5 18.3 18.2 11.8 18.4 18.5 22.9
Interest income,
net 1.9 0.7 0.7 2.0 4.2 3.6 4.0 4.1
------ ------ ------ ------ ------ ------ ------ ------
Income (loss)
before income
taxes (39.9) 15.2 19.0 20.2 16.0 22.0 22.5 27.0
Provision (benefit)
for income taxes 2.2 (15.6) (0.9) (0.7) 1.9 6.8 8.8 10.6
------ ------ ------ ------ ------ ------ ------ ------
Net income
(loss) (1)(2) (42.1)% 30.8% 19.9% 20.9% 14.1% 15.2% 13.7% 16.4%
====== ====== ====== ====== ====== ====== ====== =====
- -----------------------
(1) In the quarter ended March 31, 1995, the Company recorded a one-time
charge of $1,442,000 (60% of sales for such quarter) related to
acquired in-process research and development.
(2) Excludes accretion of mandatorily redeemable convertible preferred
stock.
The Company has experienced quarterly fluctuations in operating results
caused by various factors, including the timing of orders by major
customers, customer inventory levels, shifts in product mix, the
incurrence of acquisition-related costs and general conditions in the
healthcare industry which have reduced capital equipment budgets and
delayed or reduced the adoption of teleradiology, and expects that these
fluctuations will continue.
Gross margins declined after the first quarter of 1995 due to the
acquisition of Imagraph on March 31, 1995 and the lower margins on the
Imagraph video board products. In 1996, gross margins increased due to
better utilization of manufacturing overhead.
Operating expenses for the last three quarters of 1995 increased
significantly due to the acquisitions of XRS and Imagraph. In 1996,
operating expenses fluctuated due to increased headcount and increased
operating volume. Operating expenses declined as a percent of sales due
to increased sales volume.
The Company typically does not obtain long-term volume purchase contracts
from its customers, and a substantial portion of the Company's backlog is
scheduled for delivery within 90 days or less. Customers may cancel
orders and change volume levels or delivery times without penalty.
Quarterly sales and operating results therefore depend on the volume and
timing of the backlog as well as bookings received during the quarter. A
significant portion of the Company's operating expenses are fixed, and
planned expenditures are based primarily on sales forecasts and product
development programs. If sales do not meet the Company's expectations in
any given period, the adverse impact on operating results may be magnified
by the Company's inability to adjust operating expenses sufficiently or
quickly enough to compensate for such a shortfall.
LIQUIDITY AND CAPITAL RESOURCES
The Company has financed its activities primarily from net cash provided
by operations, which contributed approximately $2.1 million in 1996, $1.9
million in 1995 and $1.4 million in 1994. Net cash used in investing
activities included $2.3 million used in 1995 to acquire XRS and Imagraph.
On November 14, 1995, the Company successfully completed an initial public
offering, raising $12.2 million, net of underwriting discounts and
expenses.
At December 31, 1996, the Company had cash and cash equivalents of
approximately $18.4 million and working capital of approximately $24.1
million. The Company believes that its existing cash, cash equivalents
and funds to be generated by operations will satisfy the Company's
cashflow requirements through at least 1997. Thereafter, if cash
generated from operations is insufficient to satisfy the Company's
projected requirements, the Company may be required to sell additional
equity or debt securities or obtain bank or other credit facilities.
There can be no assurance that the Company will be able to sell such
securities or obtain such credit facilities on acceptable terms in the
future, if at all. The sale of additional equity or debt securities could
result in additional dilution to the Company's stockholders.
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Quarterly supplementary data is included as part of Item 7, "Management's
Discussion and Analysis of Financial Condition and Results of Operations."
The Company's consolidated financial statements required by this item are
set forth below.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Consolidated Financial Statements: Page
Report of Independent Accountants 19
Consolidated Balance Sheets at December 31, 1996 and 1995 20
Consolidated Statements of Income for the three years
ended December 31, 1996 21
Consolidated Statements of Cash Flows for the three years
ended December 31, 1996 22
Consolidated Statements of Stockholders' Equity (Deficit)
for the three years ended December 31, 1996 23
Notes to Consolidated Financial Statements 24
Financial Statement Schedule for the three years
ended December 31, 1996:
Schedule II - Valuation and Qualifying Accounts 33
All other financial statement schedules are omitted because the
information called for is not present in amounts sufficient to require
submission of the schedules or because the information is shown either in
the financial statements or the notes thereto.
REPORT OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and Stockholders of Lumisys Incorporated
In our opinion, the consolidated financial statements listed in the
accompanying index present fairly, in all material respects, the financial
position of Lumisys Incorporated and its subsidiaries at December 31, 1996
and 1995, and the results of their operations and their cash flows for
each of the three years in the period ended December 31, 1996, in
conformity with generally accepted accounting principles. These financial
statements are the responsibility of the Company's management; our
responsibility is to express an opinion on these statements based on our
audits. We conducted our audits of these statements in accordance with
generally accepted auditing standards which require that we plan and
perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting
principles used and significant estimates made by management, and
evaluating the overall financial statement presentation. We believe that
our audits provide a reasonable basis for the opinion expressed above.
PRICE WATERHOUSE LLP
San Jose, California
January 22, 1997
LUMISYS INCORPORATED
CONSOLIDATED BALANCE SHEETS
December 31,
-------------------
1996 1995
-------- --------
(in thousands, except
per share amounts)
ASSETS
Current assets:
Cash and cash equivalents $ 18,438 $ 11,426
Short-term investments --- 3,934
Accounts receivable, net of
allowances of $296 and $249 3,199 2,410
Inventories (Note 3) 3,053 3,003
Deferred tax asset 1,429 1,114
Other current assets 453 294
-------- --------
Total current assets 26,572 22,181
Property and equipment, net (Note 3) 345 162
Other assets 173 400
-------- --------
$ 27,090 $ 22,743
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 823 $ 1,525
Accrued expenses (Note 3) 1,604 1,468
-------- --------
Total current liabilities 2,427 2,993
-------- --------
Commitments (Note 8)
Stockholders' equity:
Preferred stock, $0.001 par value;
5,000 shares authorized; no shares
issued and outstanding --- ---
Common stock, $0.001 par value;
25,000 shares authorized; 6,415
and 6,240 shares issued and outstanding 6 6
Additional paid-in capital 23,887 22,702
Retained earnings (accumulated deficit) 918 (2,521)
Notes receivable from stockholders (114) (297)
Deferred compensation related
to stock options (34) (140)
-------- --------
Total stockholders' equity 24,663 19,750
-------- --------
$ 27,090 $ 22,743
======== ========
The accompanying notes are an integral part of these financial statements.
LUMISYS INCORPORATED
CONSOLIDATED STATEMENTS OF INCOME
Year ended December 31,
------------------------------
1996 1995 1994
------ ------ ------
(in thousands, except per share amounts)
Sales $23,022 $17,662 $ 8,807
Cost of sales 10,505 8,228 4,042
------ ------ ------
Gross profit 12,517 9,434 4,765
------ ------ ------
Operating expenses:
Sales and marketing 1,949 1,606 851
Research and development 4,145 2,946 1,496
General and administrative 2,238 1,832 712
Acquired in-process research
and development --- 1,442 ---
------ ------ ------
Total operating expenses 8,332 7,826 3,059
------ ------ ------
Income from operations 4,185 1,608 1,706
Interest income, net 916 223 95
------ ------ ------
Income before income taxes 5,101 1,831 1,801
Provision (benefit) for
Income taxes 1,662 (762) 95
------ ------ ------
Net income 3,439 2,593 1,706
Accretion of mandatorily
redeemable convertible
preferred stock --- --- 96
------ ------ ------
Net income attributable
to common stock $ 3,439 $ 2,593 $ 1,610
====== ====== ======
Net income per share (Note 2) $ 0.50 $ 0.49 $ 0.34
====== ====== ======
Shares used to compute net
income per share (Note 2) 6,829 5,305 4,998
====== ====== ======
The accompanying notes are an integral part of these financial statements.
LUMISYS INCORPORATED
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year ended December 31,
----------------------
1996 1995 1994
------ ------ ------
(in thousands)
Cash flows from operating activities
Net income $3,439 $2,593 $1,706
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization 176 199 64
Provision for doubtful accounts 47 165 (12)
Provision for obsolete inventories 102 375 145
Deferred income taxes (315) (1,114) ---
Deferred compensation related to stock options 37 33 ---
Interest on notes receivable from shareholders (8) (14) (8)
In-process acquired research and development --- 1,442 ---
Changes in assets and liabilities (net
of effects of Imagraph and XRS acquisitions):
Accounts receivable (836) (556) (492)
Inventories (152) (1,657) (448)
Other current assets (159) (180) 20
Other assets 227 (100) ---
Accounts payable (702) 414 68
Accrued expenses 136 280 362
------ ------ ------
Net cash provided by operating activities 1,992 1,880 1,405
------ ------ ------
Cash flows from investing activities:
Sales (purchases) of short-term investments 3,934 (3,934) ---
Purchases of property and equipment (359) (108) (61)
Purchase of Imagraph --- (1,800) ---
Purchase of XRS --- (200) ---
Purchase of minority interest
in affiliated company --- (300) ---
------ ------ ------
Net cash provided by (used in) investing activities 3,575 (6,342) (61)
------ ------ ------
Cash flows from financing activities:
Proceeds from sale of common stock, including tax
benefit 1,254 12,255 4
Payment on notes receivable from stockholders 191 --- 9
------ ------ ------
Net cash provided by financing activities 1,445 12,255 13
------ ------ ------
Net increase in cash equivalents 7,012 7,793 1,357
Cash and cash equivalents at beginning of period 11,426 3,633 2,276
------ ------ ------
Cash and cash equivalents at end of period $18,438 $11,426 $ 3,633
------ ------ ------
Supplemental disclosures of cash flow information:
Cash paid for income taxes $ 951 $ 251 $ 18
Supplemental schedule of noncash investing and financing activities:
Accretion of mandatorily redeemable
convertible preferred stock $ --- $ --- $ 96
Common stock issued for notes receivable --- --- 275
Common stock issued for purchase of XRS and
to consultant --- 33 ---
Series C mandatorily redeemable convertible
preferred stock issued for purchase
of Imagraph --- 200 ---
Deferred compensation related to stock options
reversed for terminated employees 69 --- ---
The accompanying notes are an integral part of these financial statements.
LUMISYS INCORPORATED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
Retained Notes Deferred Total
Earnings Rec'ble Comp. Stock-
Common Stock Add'l (Accumu- from Related holders'
------------- Paid-in ated Stock- to Stock Equity
Shares Amount Capital Deficit) holders Options (Deficit)
------ ------ ------- -------- -------- --------- ---------
Balance at December
31, 1993 1,670 $ --- $ 38 $ (6,724) $ (9) $ --- $ (6,695)
Exercise of
stock options 464 2 277 --- --- --- 279
Advances to
executives for
exercise of
stock options --- --- --- --- (275) --- (275)
Payment on note
receivable from
stockholder --- --- --- --- 9 --- 9
Interest on note
receivable from
stockholder --- --- --- --- (8) --- (8)
Accretion of
mandatorily
redeemable
convertible
preferred stock --- --- --- (96) --- --- (96)
Net income --- --- --- 1,706 --- --- 1,706
------ ------ ------ ------- ------- -------- --------
Balance at December
31, 1994 2,134 2 315 (5,114) (283) --- (5,080)
Exercise of
stock options 35 --- 22 --- --- --- 22
Deferred
compensation
related to
stock options --- --- 173 --- --- (173) ---
Amortization
of deferred
compensation --- --- --- --- --- 33 33
Interest on note
receivable from
stockholder --- --- --- --- (14) --- (14)
Issuance of common
stock to Director 19 --- 23 --- --- --- 23
Issuance of common
stock in
connection with
acquisition of
XRS and to
consultant 27 --- 33 --- --- --- 33
Conversion of
mandatorily
redeemable
convertible
preferred
stock 2,275 2 9,928 --- --- --- 9,930
Issuance of
common stock in
initial public
offering 1,750 2 12,208 --- --- --- 12,210
Net income --- --- --- 2,593 --- --- 2,593
------ ------ ------ ------- ------- -------- --------
Balance at December
31, 1995 6,240 6 22,702 (2,521) (297) (140) 19,750
Exercise of
stock options 151 --- 171 --- --- --- 171
Amortization
of deferred
compensation --- --- --- --- --- 37 37
Tax benefit for
disqualified
dispositions and
exercise of
non-qualified
stock options --- --- 1,026 --- --- --- 1,026
Deferred
compensation
related to stock
options reversed
for terminated
employees --- --- (69) --- --- 69 ---
Interest on notes
receivable from
stockholders --- --- --- --- (8) --- (8)
Payments on notes
receivable from
stockholders --- --- --- --- 191 --- 191
Issuance of common
stock under
employee stock
purchase plan 28 --- 177 --- --- --- 177
Shares canceled in
connection with
acquisition
of XRS (4) --- (16) --- --- --- (16)
Cost of issuance
of common stock --- --- (104) --- --- --- (104)
Net income --- --- --- 3,439 --- --- 3,439
------ ------ ------ ------- ------- -------- --------
Balance at December
31, 1996 6,415 $ 6 $23,887 $ 918 $ (114) $ (34) $ 24,663
===== ===== ======= ======= ====== ======= ========
The accompanying notes are an integral part of these financial statements.
LUMISYS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 - THE COMPANY
Lumisys Incorporated (the "Company") designs, manufactures, and markets a
family of precision digitizers that convert images on film or video into
digital format. The Company commenced operations on February 4, 1987, and
operates in one industry segment.
Certain Equity Transactions
In conjunction with an initial public offering of the Company's Common
Stock (the "Offering") in 1995, all outstanding shares of mandatorily
redeemable convertible Preferred Stock automatically converted into Common
Stock upon the closing of the Offering.
In September and October 1995, the Company's Board of Directors
authorized, and the stockholders approved, the reincorporation of the
Company in Delaware and the associated exchange of four shares of Common
Stock and four shares of mandatorily redeemable convertible Preferred
Stock into one share of each corresponding class and series of stock of
the Delaware successor (resulting in a one-for four reverse stock split of
the Company's Common and Preferred Stock). All applicable share and per
share amounts of Common and Preferred Stock have been retroactively
adjusted to reflect this reverse stock split. Effective upon the closing
of the Offering, the Company was authorized to issue 25,000,000 shares of
Common Stock and 5,000,000 shares of undesignated Preferred Stock and the
Board of Directors have the authority to issue the undesignated Preferred
Stock in one or more series and to fix the rights, preferences, privileges
and restrictions thereof.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Management Estimates and Assumptions
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the
financial statements and reported amounts of sales and expenses during the
reporting period. Actual results could differ from those estimates.
Principles of Consolidation
The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiaries. All significant intercompany
transactions and balances have been eliminated.
Revenue Recognition
Revenues are recognized when products are shipped. Sales to international
customers, primarily located in Europe, represented, 12%, 9% and 17% of
total sales in 1996, 1995 and 1994, respectively. All transactions are
denominated in U.S. dollars.
The following table summarizes the percentage of total sales from
customers accounting for more than 10% of the Company's total sales in any
one of the three years ended December 31, 1996:
Year ended December 31,
------------------------
Customer 1996 1995 1994
-------- ---- ---- ----
A 9% 11% 14%
B 6% 12% 15%
C 8% 10% 16%
D 5% 5% 11%
Cash Equivalents and Short-term Investments
The Company considers all debt instruments with maturities of three months
or less when purchased to be cash equivalents. The Company generally
invests its available cash in commercial paper and money market funds with
several financial institutions.
The Company has categorized its short-term investments as available for
sale. Realized gains or losses are determined using the specific
identification method and are reflected in income. Net unrealized gains
or losses are recorded directly in stockholders' equity except that those
unrealized losses which are deemed to be other than temporary are
reflected in the income statement. As of December 31, 1995, short-term
investments consisted of a marketable debt security and its carrying value
approximated cost. As of December 31, 1996, the Company did not have any
short-term investments.
Inventories
Inventories are stated at the lower of cost, determined using the first-
in, first-out method, or market, and reserves are provided for obsolete,
slow-moving or unsaleable inventory.
Property and Equipment
Property and equipment are stated at cost. Depreciation is provided using
the straight-line method over the estimated useful lives of the respective
assets, generally three years. Leasehold improvements are amortized using
the straight-line method over the lesser of the remaining lease terms or
the estimated useful lives of the related assets.
Research and Development
Research and development costs are expensed as incurred.
Software Development Costs
Software development costs are included in research and development and
are expensed as incurred. Certain software development costs are
capitalized once technological feasibility is established, which the
Company defines as the completion of a working model. The capitalized
cost is then amortized on a straight-line basis over the estimated product
life, or on the ratio of current sales to total projected product sales,
whichever method results in greater amortization. To date, the period
between achieving technological feasibility and the general availability
of such software has been short and software development costs qualifying
for capitalization have been insignificant.
Warranty
Upon product shipment, the Company provides for the estimated cost that
may be incurred under its product warranties.
Income Taxes
A deferred income tax asset or liability is established for the expected
future consequences resulting from the differences between the financial
reporting and income tax bases of assets and liabilities and from net
operating loss and tax credit carryforwards.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to significant
concentrations of credit risk consist primarily of cash and cash
equivalents and accounts receivable. The Company limits the amount of
cash invested with any one financial institution. The Company's trade
accounts receivable are derived primarily from sales in the United States,
Europe and the Far East. The Company's credit policy is to require
prepayment of 50% prior to shipment on domestic sales and prepayment of
100% or a letter of credit on foreign sales. Prepayments are generally
made less than one week prior to shipment. The Company's prepayment
policy has not resulted in significant unearned revenue balances at the
reported balance sheet dates. The Company performs ongoing credit
evaluations of its customers' financial condition and may modify its sales
terms in certain circumstances based on these reviews. The Company
maintains reserves for potential credit losses; historically, such losses
have been minor and within management's expectations.
Net Income Per Share
Net income per share is computed using the weighted average number of
outstanding shares of Common Stock and common stock equivalents, assuming
the conversion of mandatorily redeemable convertible Preferred Stock into
common shares, which occurred upon completion of the Offering, and the
exercise of stock options (using the treasury stock method). Common stock
equivalents are excluded from the computation if their effect is anti-
dilutive, except that pursuant to the requirements of the Securities and
Exchange Commission, mandatorily redeemable convertible preferred stock
(using the if converted method) and common equivalent shares (using the
treasury stock method and the initial public offering price) issued
subsequent to August 31, 1994 through November 14, 1995 have been included
in the computation as if they were outstanding for all periods presented
prior to the offering effective date, November 14, 1995.
Recently Issued Accounting Pronouncement
In 1996, the Company implemented the disclosure requirements of Statement
of Financial Accounting Standards No. 123 ("SFAS 123"), "Accounting for
Stock-Based Compensation." The Company's adoption of SFAS 123 in 1996
does not have a material effect on the Company's financial position or
results of operations, as the Company elected to continue to measure the
compensation cost of stock option plans using the intrinsic value based
method.
NOTE 3 - COMPOSITION OF CERTAIN FINANCIAL STATEMENT AMOUNTS
December 31,
--------------------
1996 1995
------- -------
(in thousands)
Inventories:
Raw materials $ 2,607 $ 2,283
Work-in-process 422 774
Finished goods 959 779
------- -------
3,988 3,836
Less: inventory reserves (935) (833)
------- -------
$ 3,053 $ 3,003
======= =======
December 31,
--------------------
1996 1995
------- -------
(in thousands)
Property and equipment:
Machinery and equipment $ 1,045 $ 686
Furniture and fixture 14 14
Leasehold improvements 33 33
------- -------
1,092 733
Less: accumulated
depreciation and
amortization (747) (571)
------- -------
$ 345 $ 162
======= =======
Accrued expenses:
Payroll and related
benefits $ 670 $ 538
Warranty 471 533
Other 463 397
------- -------
$ 1,604 $ 1,468
======= =======
NOTE 4 - ACQUISITIONS
Imagraph Corporation
On March 31, 1995, the Company purchased all the outstanding shares of
Imagraph Corporation ("Imagraph"), a developer and manufacturer of
advanced graphics controllers and frame grabbers, in exchange for
$1,800,000 in cash and 36,845 shares of Series C mandatorily redeemable
convertible Preferred Stock. The transaction was accounted for as a
purchase; accordingly, the purchase price was allocated to the assets
acquired and liabilities assumed based upon their estimated fair market
values at the date of the acquisition. The in-process research and
development represents the estimated current fair market value, using a
risk-adjusted income approach, of specifically identified technologies
which had not reached technological feasibility and had no alternative
future uses. The purchased technology met the technological feasibility
criteria for capitalization and estimated current fair market value was
determined using a risk-adjusted income approach. The results of Imagraph
are included in the Company's operations commencing from the date of
acquisition. The allocation of the purchase price, which is based
principally on an independent appraisal, is as follows (in thousands):
Accounts receivable $ 855
Inventories 940
Property and equipment 49
In-process research and development 877
Purchased technology 120
Other assets 45
Accounts payable assumed (717)
Other liabilities assumed (169)
-----
Total purchase price $2,000
=====
The total purchase price is derived as follows:
Cash payment $1,800
Issuance of Series C mandatorily
redeemable convertible
preferred stock 200
-----
$2,000
=====
X-Ray Scanner Corporation
On March 2, 1995, the Company purchased all the outstanding shares of X-
Ray Scanner Corporation ("XRS"), a developer and manufacturer of medical
film scanning digitizers, in exchange for $200,000 in cash, 15,058 shares
of the Company's Common Stock and $10,000 in acquisition expenses. The
transaction was accounted for using the purchase method; accordingly, the
purchase price was allocated to the assets acquired and liabilities
assumed based upon their estimated fair market values at the date of
acquisition. The in-process research and development represents the
estimated current fair market value, using a risk-adjusted income
approach, of specifically identified technologies which had not reached
technological feasibility and had no alternative future uses. The results
of XRS are included in the Company's operations commencing from the date
of acquisition. Prior years results of XRS are not material in relation
to the results of operations of the Company. The allocation of the
purchase price is as follows (in thousands):
In-process research and development $ 565
Other assets 25
Accounts payable assumed (150)
Other liabilities assumed (212)
-----
Total purchase price $ 228
=====
The total purchase price is derived as follows:
Cash payment $ 200
Issuance of Common Stock 18
Other expenses 10
-----
$ 228
=====
Pro Forma Information
The following pro forma information reflects the results of operations for
the years ended December 31, 1995 and 1994 as if the acquisition of
Imagraph had occurred as of January 1, 1994, and after giving effect to
certain adjustments. These pro forma results have been prepared for
comparative purposes only and do not purport to be indicative of what
operating results would have been had the acquisition actually taken place
as of January 1, 1994, or what operating results may occur in the future.
December 31,
--------------------
1995 1994
------- -------
(in thousands, except per share amounts)
Sales $19,056 $13,604
====== ======
Net income $ 2,724 $ 1,856
====== ======
Net income per share $ 0.51 $ 0.37
====== ======
NOTE 5 - INCOME TAXES
The provision (benefit) for income taxes consists of the following (in
thousands):
Year ended December 31,
-------------------------------
1996 1995 1994
------- ------- -------
Current:
Federal $ 1,619 $ 126 $ 65
State 358 226 30
------- ------- -------
1,977 352 95
------- ------- -------
Deferred:
Federal (365) (751) ---
State 50 (363) ---
------- ------- -------
(315) (1,114) ---
------- ------- -------
$ 1,662 $ (762) $ 95
======= ======= =======
During 1996, income taxes payable was reduced by approximately $1.0
million in connection with the exercise of non-qualified stock options.
The provision (benefit) reconciles to the amount computed by multiplying
income before tax by the U.S. statutory rate (34%) as follows (in
thousands):
Year ended December 31,
-------------------------------
1996 1995 1994
------- ------- -------
Provision at statutory rate $ 1,734 $ 623 $ 612
Utilization of net operating
loss carryforwards --- (940) (539)
Decrease in valuation allowance (384) (1,114) ---
Nondeductible acquired research
and development --- 490 ---
State taxes, net of federal benefit 313 149 20
Other (1) 30 ---
------- ------- -------
$ 1,662 $ (762) $ 95
======= ======= =======
Deferred tax assets comprise the following (in thousands):
December 31,
------------------------
1996 1995
-------- --------
Net operating loss carryforwards $ 303 $ 303
Tax credit carryforwards 160 571
Nondeductible accruals 1,167 810
Depreciation and amortization 180 195
-------- --------
1,810 1,879
Deferred tax assets valuation allowance (381) (765)
-------- --------
Net deferred tax assets $ 1,429 $ 1,114
======== ========
Management believes that the available objective evidence, including the
recent acquisitions made by the Company and the necessary expenditures for
research and development and for marketing in the high technology segment
it pursues, creates uncertainty regarding the attainment of sufficient
profitability to realize the deferred tax assets and therefore a partial
valuation allowance has been recorded.
At December 31, 1996, the Company had net operating loss carryforwards
available to reduce income taxes for federal and state income tax purposes
of approximately $800,000 and $500,000, respectively; such carryforwards
expire through 2007. In addition, at December 31, 1996, the Company had
research and development credit carryforwards available to reduce income
taxes for federal and state income tax purposes of approximately $40,000
and $120,000 which expire from 2004 to 2010.
NOTE 6 - STOCK PLANS
The Company initially reserved 45,000 shares of Common Stock for issuance
under its 1987 Stock Option Plan (the "1987 Plan"). During 1990, the
Board of Directors authorized an additional 580,000 shares to be reserved
for issuance and during each of the years ended December 31, 1992, 1994
and 1995, the Board of Directors authorized an additional 250,000 shares
to be reserved for issuance. The 1987 Plan provides for the grant of
incentive stock options and nonstatutory stock options (designated
"Supplemental Stock"). Incentive stock options are available for
employees, officers and employee directors and are granted at exercise
prices which are not less than 100% of fair market value on the date of
the grant. Supplemental Stock is available for employees, officers,
consultants and directors and is granted at exercise prices not less than
85% of fair market value on the date of grant. All options are to have a
term not greater than ten years from the date of grant. The Board shall
determine the number of shares for which an option can be granted.
Options granted generally vest 25 percent after one year and then ratably
at 6.25 percent per quarter over a three year period.
In September 1995, the Board of Directors determined that no additional
options would be granted under the 1987 Plan and adopted the 1995 Stock
Option Plan (the "1995 Plan") under which an aggregate of 350,000 shares
of Common Stock have been reserved for issuance upon exercise of options
granted to employees, officers and employee directors of and consultants
to the Company. The 1995 Plan will terminate in September 2005, unless
terminated earlier by the Board of Directors.
The 1995 Plan provides for the grant of both incentive stock options and
nonstatutory stock options (designated "Supplemental Stock"). The maximum
term of options granted under the 1995 Plan is ten years. The exercise
price of incentive stock options granted under the 1995 Plan must equal at
least the fair value of the Company's Common Stock on the date of grant.
The exercise price of Supplemental Stock options under the Plan must equal
at least 85% of the fair market value of the Company's Common Stock on the
date of grant. The exercise price of options granted to any person who at
the time of grant owns stock possessing more than 10% of the total
combined voting power of all classes of stock must be at least 110% of the
fair market value of such stock on the date of grant and the terms of
these options cannot exceed five years. The Board shall determine the
number of shares for which an option can be granted. Options granted
under the 1995 Plan will generally vest 25 percent after one year and then
ratably at 6.25 percent per quarter over a three year period.
Under certain events, the Company has the right to repurchase, at the
original issue price, a declining percentage of certain of the common
shares issued to employees under written agreements with such employees.
The Company's right to repurchase such stock declines on a percentage
basis based on the length of the employees' continuous employment with the
Company. At December 31, 1996, 8,508 shares of Common Stock were subject
to repurchase by the Company.
The Company has recorded compensation expense for the difference between
the grant price and the deemed fair market value of the Company's Common
Stock for options granted in March 1995. Such compensation expense was
approximately $37,000 for the year ended December 31, 1996 and $33,000 for
the nine month period ended December 31, 1995. During 1996, forfeited
options resulted in a reduction of $69,000 from the maximum aggregated
compensation expense to approximately $104,000 over the vesting period of
four years.
In August 1995, the Board adopted the 1995 Non-Employee Directors Stock
Option Plan (the "Directors Plan"), which provided for the automatic grant
of options to purchase shares of Common Stock to non-employee directors of
the Company. The Directors Plan will be administered by the Board.
The maximum number of shares of Common Stock that may be issued pursuant
to options granted under the Directors Plan is 112,500. Pursuant to the
terms of the Directors Plan, each person who is elected as a director of
the Company or a compensated Chairman of the Board (a "Non-Employee
Director") will automatically be granted on option to purchase 18,750
shares of Common Stock on the date of his or her election to the Board.
On the date of adoption of the Directors Plan, each person who was then a
Non-Employee Director of the Company and who had not received within the
one-year period prior to adoption of the Directors Plan either an option
grant or other right to purchase shares of Common Stock, was granted an
option to purchase 18,750 shares of Common Stock under the Directors Plan.
Thereafter, each Non-Employee Director will automatically be granted an
option to purchase an additional 18,750 shares of Common Stock under the
Directors Plan on the date any and all previous options or stock purchases
by such person either under the Directors Plan or otherwise become fully
vested. Options granted under the Directors Plan will vest 25 percent
after one year and then ratably at 6.25 percent per quarter thereafter over
a three year period.
No options granted under the Directors Plan may be exercised later than
ten years from the date of grant. The exercise price of options under the
Directors Plan must be equal to the fair market value of the Common Stock
on the date of grant. Options granted under the Directors Plan are
generally nontransferable. The Directors Plan will terminate August 2005
unless terminated earlier by the Board.
Pursuant to the Directors Plan, in August 1995 each of two Non-Employee
Directors was granted an option to purchase 18,750 shares of Common Stock
at an exercise price of $6.00 per share.
In September 1995, the Company's Board of Directors approved the 1995
Employee Stock Purchase Plan (the "Purchase Plan") and reserved 150,000
shares of Common Stock for issuance to eligible employees. The Purchase
Plan permits eligible employees to purchase Common Stock through periodic
payroll deductions of up to 10% of their annual compensation. Each
offering period will have a duration of 12 months and shares of Common
Stock will be purchased for each participant at semi-annual intervals
during each offering period. The price at which the Common Stock is
purchased under the Purchase Plan is equal to 85 percent of the lower of
the fair value on the commencement date of each offering period or the
semi-annual purchase date. As of December 31, 1996, 28,450 shares had
been issued under the Purchase Plan.
At December 31,1996, the Company has three stock-based compensation plans,
as described above. The Company has elected to continue to apply APB
Opinion 25 and related Interpretations in accounting for its plans.
Accordingly, no compensation cost has been recognized for its fixed stock
option plans and its stock purchase plan. Had compensation cost for the
Company's three stock-based compensation plans been determined based on
the fair value at the grant dates for awards under those plans consistent
with the method of SFAS 123, the Company's net income and net income per
share would have been reduced to the pro forma amounts indicated below (in
thousands, except per share amounts):
1996 1995
Net income As reported $ 3,439 $ 2,593
Pro forma $ 3,197 $ 2,514
Net income per share As reported $ 0.50 $ 0.49
Pro forma $ 0.47 $ 0.47
The fair value of each option grant is estimated on the date of grant
using the Black-Scholes option-valuation model with the following
weighted-average assumptions used for grants in 1996 and 1995,
respectively: dividend yield of 0 percent for both years; expected
volatility of 57.8 and 59.8 percent, risk-free interest rates of 6.01 and
6.26; and expected lives of 3 years for non-officer/director and 5 years
for officers and directors for both years.
A summary of the Company's stock option activity is presented below:
Weighted
Options Average Price
-------- -------------
Outstanding at December 31, 1993 678,813 $0.59
Options granted 198,625 $0.60
Options exercised (464,546) $0.60
Options forfeited (17,267) $0.60
--------
Outstanding at December 31, 1994 395,621 $0.59
Options granted 465,238 $3.66
Options exercised (34,683) $0.65
Options forfeited (13,048) $1.00
--------
Outstanding at December 31, 1995 813,128 $2.34
Options granted 153,225 $9.61
Options exercised (151,141) $1.13
Options forfeited (139,172) $4.60
--------
Outstanding at December 31, 1996 676,040 $3.79
========
Vested at December 31, 1996 273,287
========
Available for future grant at
December 31, 1996 287,625
========
The following table summarizes information about fixed stock options
outstanding at December 31, 1996:
Options Outstanding Options Vested
------------------------------- -----------------------
Weighted-
Average Weighted- Weighted-
Number Remaining Average Average
Range of Out- Contractual Exercise Number Exercise
Exercise Prices Standing Life Price Vested Price
- --------------- -------- ----------- --------- -------- ----------
$0.26 to $ 0.60 265,963 6.66 years $0.59 198,098 $0.59
1.20 to 1.20 121,634 8.20 1.20 37,747 1.20
4.00 to 6.00 133,255 8.60 5.79 36,784 5.72
8.00 to 11.44 155,188 9.71 9.59 658 8.00
------- --------
$0.26 to $11.44 676,040 8.02 $3.79 273,287 $1.38
======= ========
Using the Black-Scholes option-valuation model, the weighted average fair
value of options granted in 1996 and 1995 is $5.09 and $2.06 respectively.
The fair value of the employees' purchase rights under the Purchase Plan,
which is described above, was estimated using the Black-Scholes option-
valuation model with the following assumptions for 1996 and 1995,
respectively: dividend yield of 0 percent for both years; an expected
life of 1 year for both years; expected volatility of 59 and 56 percent;
and risk-free interest rates of 5.52 and 5.96 percent. The weighted-
average fair value of those purchase rights granted in 1996 and 1995 was
$2.74 per share for both years.
NOTE 7 - NOTES RECEIVABLE FROM RELATED PARTIES
During May 1994, the Company made loans totaling $275,000 to certain
executives and directors pursuant to the Company's 1987 Stock Option Plan.
The loans are secured by 458,500 shares of the Company's Common Stock.
The loans bear interest at the lesser of 4.94 percent per annum or the
maximum rate permissible by law. Accrued interest is payable annually in
arrears. The loans are due on the earlier of May 31, 1997 or upon the
borrower's termination of employment with the Company. Notes receivable
deducted from stockholders' equity (deficit) at December 31, 1996, 1995,
1994 and 1993 include loan balances plus accrued interest.
During 1995, the Company made a loan totaling $125,000 to an employee of
the Company. The loan bears interest at 7.96 percent per annum and is
payable at a rate of $25,000 plus accrued interest annually commencing
March 1, 1996. In addition, the Company has entered into a non-
competition agreement with the same employee at a rate of $25,000 per year
over a five year period commencing March 1, 1995.
NOTE 8 - COMMITMENTS
The Company leases its facilities under noncancelable operating leases
which expire at various dates through 2000. Future minimum lease
commitments are as follows (in thousands):
Year ending
December 31,
------------
1997 $277
1998 221
1999 221
2000 221
-----
$940
=====
Total rent expense was approximately $441,000, $318,000 and $173,000 for
1996, 1995 and 1994, respectively.
Schedule II: Valuation and Qualifying Accounts
Balance at Balance
beginning at end
of year Additions Deductions of year
---------- --------- ---------- -------
Year ended December 31, 1994:
Allowance for doubtful accounts $ 96 $ 62 $ (74) $ 84
Inventory reserves $ 506 $ 145 $(130) $ 521
Year ended December 31, 1995:
Allowance for doubtful accounts $ 84 $ 172 $ (7) $ 249
Inventory reserves $ 521 $ 402 $ (90) $ 833
Year ended December 31, 1996:
Allowance for doubtful accounts $ 249 $ 50 $ (3) $ 296
Inventory reserves $ 833 $ 434 $(332) $ 935
Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None.
PART III
Item 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The information contained on pages 2 and 3 of Lumisys Incorporated's Proxy
Statement dated April 8, 1997 with respect to directors of the Company, is
incorporated herein by reference in response to this item.
The executive officers of the Company and their ages as of December 31,
1996 are as follows:
Name Age Position
Stephen J. Weiss 58 President, Chief Executive Officer and Director
Craig L. Klosterman 42 Chief Operating and Chief Financial Officer
John M. Burgess 52 Vice President, Sales
Linden J. Livoni 48 Vice President, Engineering
Kuldip K. Ahluwalia 40 Vice President, Marketing and Business
Development
Stephen J. Weiss has served as a member of the Company's Board of
Directors, President and Chief Executive Officer since joining the Company
in January 1990. Prior to that time, Mr. Weiss was a founder of Virtual
Imaging, a medical imaging company, where he last held the position of
President. From 1971 to 1985, Mr. Weiss was an Executive Vice President
of ADAC Laboratories, a medical imaging company.
Craig L. Klosterman has served as the Chief Financial Officer since
February 1993 and also as the Company's Chief Operating Officer since
October 1994. Mr. Klosterman also served as Vice President, Operations
for the Company from January 1994 through October 1994. From 1988 to
1992, he worked at Voysys Corporation, a telephone communications company,
where he last held the position of Vice President of Finance and from 1987
through 1988 he served as controller of Silicon Solutions Corporation, a
subsidiary of Zycad Corporation, a computer-aided engineering company.
John M. Burgess has served as the Company's Vice President of Sales since
May 1990. From 1986 to 1990, Mr. Burgess served as Vice President, Sales
and Marketing for Diasonics, a medical imaging company. Prior to joining
Diasonics, Mr. Burgess served as an Executive Vice President of ADAC
Laboratories.
Linden J. Livoni has served as the Company's Vice President of Engineering
since January 1992. Prior to that time, Mr. Livoni spent six years as
Director of Engineering at Greyhawk Systems, Inc., a high-resolution
display company. Previously, Mr. Livoni served as Director of Engineering
for the Digital Radiography Division of Diasonics.
Kuldip K. Ahluwalia has served as the Company's Vice President of
Marketing and Business Development since December 1996. From 1994 through
1996, Mr. Ahluwalia served as Marketing Manager for Toshiba America
Medical Systems, a medical imaging company. Prior to joining Toshiba, Mr.
Ahluwalia held various sales and marketing positions with General Electric
Medical Systems.
Item 11. EXECUTIVE COMPENSATION
The information contained on pages 10 through 13 of Lumisys Incorporated's
Proxy Statement dated April 8, 1997 with respect to executive compensation
and transactions, is incorporated herein by reference in response to this
item.
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information contained on pages 9 and 10 of Lumisys Incorporated's
Proxy Statement dated April 8, 1997 with respect to security ownership of
certain beneficial owners and management, is incorporated herein by
reference in response to this item.
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The information contained on page 16 of Lumisys Incorporated's Proxy
Statement dated April 8, 1997, with respect to certain transactions, is
incorporated herein by reference in response to this item.
PART IV
Item 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-
K
(1) Financial Statements - See Item 8 of this report
(2) Financial Statement Schedules - See Item 8 of this report
(3) Index to Exhibits
Exhibit
Number Description of Document
2.1 Form of Agreement and Plan of Merger between Lumisys Incorporated
("Lumisys California") and Lumisys Merger Corporation ("Lumisys
Delaware") (1)
3.1 Amended and Restated Certificate of Incorporation of Lumisys
Delaware (2)
3.2 Certificate of Incorporation of the Company, filed with the
Delaware
Secretary of State on November 17, 1995 (2)
3.3 Bylaws of Lumisys Delaware (1)
3.4 Certificate of Amendment to Amended and Restated Certificate of
Incorporation of Lumisys Delaware, filed with the Delaware
Secretary of State on October 26, 1995 (1)
4.1 Reference is made to Exhibits 3.1 through 3.3
4.2 Specimen stock certificate (1)
10.1 Form of Indemnity Agreement entered into between the Company and
its directors and officers (1)
*10.2 The Company's 1987 Stock Option Plan (the "1987 Plan") (1)
*10.3 Form of Incentive Stock Option under the 1987 Plan (1)
*10.4 Form of Supplemental Stock Option under the 1987 Plan (1)
*10.5 Form of Early Exercise Agreement under the 1987 Plan (1)
*10.6 The Company's 1995 Stock Option Plan (the "1995 Plan") (1)
*10.7 Form of Incentive Stock Option under the 1995 Plan (1)
*10.8 Form of Supplemental Stock Option under the 1995 Plan (1)
*10.9 Form of Early Exercise Agreement under the 1995 Plan (1)
*10.10 The Company's 1995 Employee Stock Purchase Plan (1)
*10.11 The Company's 1995 Non-Employee Directors' Stock Option Plan (1)
10.12 Stock Purchase Agreement dated as of March 31, 1995 among the
Company, Imagraph Corporation and Microfield Graphics, Inc. (1)
10.13 The Company's Amended and Restated Information and Registration
Rights Agreement dated as of April 26, 1991, as amended (1)
10.14 Registration Rights Granted to Nicholas K. Sheridon, dated
December 15, 1987 between the Company and Nicholas K. Sheridon (1)
10.16 Lease, dated January 1, 1993 between Teachers Realty Corporation
and Imagraph Corporation (1)
10.17 Industrial Real Estate Lease, dated October 12, 1995, by and
between the Company and APT-Cabot California, Inc. (1)
21.1 Subsidiaries of the Company (1)
23.1 Consent of Price Waterhouse LLP
- ---------------------------------------------------
(1) Incorporated by reference to the exhibit bearing the same number in the
Company's Form S-1 Registration Statement declared effective November 14,
1995 (File No. 33-97230).
(2) Incorporated by reference to the exhibit bearing the same number in the
Company's Form 10-K for the year ended December 31, 1995.
* Management contract or compensatory plan or arrangement.
(b) Reports on Form 8-K filed in the fourth quarter of 1995
None.
(d) Financial statement schedules - The response to this portion of Item
14 is submitted as a separate section of this report.
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
LUMISYS INCORPORATED
Dated: March 28, 1997 By:/s/ Stephen J. Weiss
--------------------
Stephen J. Weiss
President, Chief
Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
Signature Title Date
/s/ Stephen J. Weiss President, Chief Executive March 28, 1997
- -------------------- Officer and Director --------------
Stephen J. Weiss (Principal Executive Officer)
/s/ Craig L. Klosterman Chief Operating and Chief March 28, 1997
- ----------------------- Financial Officer (Principal --------------
Craig L. Klosterman Financial Officer)
/s/ Douglas G. DeVivo, Ph.D. Chairman of the Board March 28, 1997
- ---------------------------- --------------
Douglas G. DeVivo, Ph.D.
/s/ C. Richard Kramlich Director March 28, 1997
- ----------------------- --------------
C. Richard Kramlich
/s/ Matthew D. Miller, Ph.D. Director March 28, 1997
- ---------------------------- --------------
Matthew D. Miller, Ph.D.
/s/ Jesse I. Treu, Ph.D. Director March 28, 1997
- ------------------------ --------------
Jesse I. Treu, Ph.D.
45
Exhibit 23.1
CONSENT OF INDEPENDENT ACCOUNTANTS
We hereby consent to the incorpoation by reference in the Registration
Statement on From S-8(No. 33-80253) of Lumisys Incorporated of our report
dated January 22, 1997 appearing on Page 19 of this Annual Report on Form
10-K.
PRICE WATERHOUSE LLP
San Jose, CA
March 28, 1997
44
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM LUMISYS
INCORPORATED CONSOLIDATED BALANCE SHEETS AT DECEMBER 31, 1996 AND CONSOLI-
DATED STATEMENTS OF INCOME FOR THE YEAR ENDED DECEMBER 31, 1996 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1000
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-START> JAN-01-1996
<PERIOD-END> DEC-31-1996
<CASH> 18438
<SECURITIES> 0
<RECEIVABLES> 3495
<ALLOWANCES> 296
<INVENTORY> 3053
<CURRENT-ASSETS> 1892
<PP&E> 1092
<DEPRECIATION> 747
<TOTAL-ASSETS> 27090
<CURRENT-LIABILITIES> 2427
<BONDS> 0
0
0
<COMMON> 6
<OTHER-SE> 24657
<TOTAL-LIABILITY-AND-EQUITY> 27090
<SALES> 23022
<TOTAL-REVENUES> 23022
<CGS> 10505
<TOTAL-COSTS> 10505
<OTHER-EXPENSES> 8332
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> (916)
<INCOME-PRETAX> 5101
<INCOME-TAX> 1662
<INCOME-CONTINUING> 3439
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 3439
<EPS-PRIMARY> .50
<EPS-DILUTED> .50
</TABLE>
